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Even if organophosphorus (OP) nerve agents were banned entirely, their presence would remain a problem as weapons 
of terror (like in Syria). Oxime antidotes currently used in medical practice still fall short of their therapeutic purpose, as 
they fail to fully restore the activity of cholinesterases, the main target for OPs. As orphan drugs, these antidotes are tested 
too seldom for anybody’s benefit. Over the last few decades, search for improved reactivators has reached new levels, 
but the translation of data obtained in vitro to in vivo application is still a problem that hinders efficient therapy. In this 
study, we tested the strengths and weaknesses of extrapolating pyridinium oxime antidotes reactivation efficiency from 
in vitro to in vivo application. Our results show that this extrapolation is possible with well-determined kinetic constants, 
but that it also largely depends on oxime circulation time and its tissue-specific distribution. This suggests that 
pharmacokinetic studies should be planned at the early stages of antidote development. Special attention should also be 
given to improving oxime distribution throughout the organism to overcome this major constraint in improving overall 
OP therapy.
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Exposure to organophosphorus compounds (OP) such 
as nerve agents and certain pesticides causes diverse health 
complications including nervous, endocrine, reproductive, 
and immune system changes (1, 2). Their acute toxicity is 
mainly the result of the inhibition of acetylcholinesterase 
(AChE; EC 3.1.1.7) activity in the central and peripheral 
nervous system. Current treatment relies on the use of 
anticholinergic drug atropine to reduce the effects of 
accumulating acetylcholine usually combined with oximes 
that reactivate phosphylated AChE (3-5). However, the 
potential of the oximes used in medical practice today, such 
as 2-PAM, HI-6, and obidoxime, is limited primarily due 
to the very specific properties of each of the enzyme-OP 
conjugates (6-9).
Just as any other drug, oximes have to comply with a 
great number of requirements to be accepted for human 
use. Antidotes of this kind fall into the category of orphan 
drugs, which means that trials are seldom performed. Even 
preclinical studies on animal models are limited due to 
ethical issues and high security regulations for work with 
OPs (1). Therefore, selecting the right compound for further 
studies based on promising in vitro results undoubtedly 
presents the greatest challenge. This is even more true when 
we consider that so many results available today still lack 
a critical angle on the oximes’ antidotal potencies and how 
Katalinić M, et al. Translation of in vitro to in vivo pyridinium oxime potential in tabun poisoning 
Arh Hig Rada Toksikol 2015;66:291-298
applicable they are in vivo. This kind of information would 
greatly help to develop more effective therapies against OP 
poisoning.
With this in mind, we tested the strengths and 
weaknesses of extrapolating pyridinium oxime antidote 
results from in vitro to in vivo application. For our study, 
we chose the oxime K048 and OP compound tabun, since 
previous antidotal research on tabun highlighted oxime 
K048 as the leading pyridinium reactivator of tabun-
inhibited AChE (10-13). As there is strong in vitro and in 
vivo evidence favouring this oxime-OP model, we believed 
that it would serve well for translation of the oximes’ 
potential as reactivator of OP-inhibited AChE to its antidotal 
potential against OP poisoning.
We focused on oxime distribution, elimination, and 
tissue-specific AChE reactivation capacity in rats exposed 
subcutaneously to a single sub-lethal dose of tabun (3/4 
LD50). This route and dose were chosen to ensure toxic 
manifestations at all levels without loading the animals with 
excess poison (that would mask the effect of the oxime). 
Oxime K048 was applied intraperitoneally in a single dose 
approximating the in vitro determined enzyme-oxime (Ki) 
or phosphorylated enzyme-oxime (KOX) dissociation 
constant (10, 12), calculated on the estimated whole body 
fluid content (15). This dose ensures oxime concentration 
that efficiently reactivates AChE in vitro (10).
The tissue in which we monitored reactivation 
determines the final outcome of OP poisoning: blood, 
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diaphragm, and brain. To be more precise, cholinesterase 
activity in blood is used as a marker of exposure to OPs 
and is considered to be the first line of defence before OPs 
reach vital sites (5, 16, 17). AChE inhibition in diaphragm 
leads to life-threatening difficulties in breathing, whereas 
inhibition in the brain has severe and long-term 
consequences, all of which lead to death.
We also followed the activity of butyrylcholinesterase 
(BChE, EC 3.1.1.8), a stoichiometric scavenger of OPs (5, 
16, 18, 19). Much effort has been put so far into improving 
BChE’s endogenous scavenging capacity, mainly by trying 
to convert it into a pseudo-catalytic scavenger by adding a 
BChE reactivation-specific oxime. Certain progress has 
been made with K048 analogues, pyridinium oximes K127 
and K117, against tabun (20) and with some non-pyridinium 
oximes against VX-, cyclosarin-, and paraoxon-BChE 
conjugates (21). Although our oxime model should be 
specific to AChE reactivation (11), data obtained on BChE 
will give additional information for the extrapolation of in 




4-(4-carbamoylpyridinium) butane dibromide) 
(Mr=460.16 g mol‒1) was a gift from Dr Kamil Kuča, 
University of Hradec Kralove, Czech Republic. It was kept 
at room temperature and dissolved in water or atropine 
immediately before use. Tabun (ethyl N,N-dimethyl 
phosphoroamidocyanidate) was purchased from NC 
Laboratory, Spiez, Switzerland. A stock solution of 
5,000 μg mL‒1 was prepared in isopropyl alcohol. Further 
dilutions were made in saline immediately before use. 
Atropine sulphate (Kemika, Zagreb, Croatia) was dissolved 
in water. Non-ionic detergent 1 % Triton X-100 was 
purchased from SERVA Electrophoresis GmbH, Heidelberg, 
Germany. Acetylthiocholine iodide (ATCh), DTNB 
(5,5’-dithiobis(2-nitrobenzoic acid)), BW284C51 
(1,5-bis(4-allyldimethyl-ammoniumphenyl)-pentane-3-one 
dibromide), ethopropazine ((10-[2-diethylaminopropyl]
phenothiazine)hydrochloride), and chemicals for high 
performance liquid chromatography (HPLC) [acetonitrile 
gradient grade LiChrosolv, disodium hydrogen phosphate 
dihydrate, citric acid monohydrate, ethylenedinitrilo 
tetraacetic acid disodium salt dihydrate (Na2EDTA), 
1-octane sulphonic acid sodium salt, perchloric acid (70 
%), and phosphoric acid] were purchased from Sigma-
Aldrich (St. Louis, MO, USA). The water used for HPLC 
was double-distilled and deionised HPLC-grade.
Animal treatment and tissue isolation
Adult male Wistar rats (240-280 g body weight) were 
kept in Macrolone cages under controlled conditions (room 
temperature 21 °C, light and dark cycles exchanging every 
12 h), received a standard diet, and had free access to water. 
This study was performed with the approval of the Ethics 
Committee of the Institute for Medical Research and 
Occupational Health, Zagreb, Croatia and the Faculty of 
Military Health Sciences in Hradec Kralove, Czech 
Republic.
The rats were divided into five groups (four animals in 
each) for every time point (0.5 h, 1 h, and 6 h): (a) saline 
(control group); (b) K048; (c) tabun; (d) tabun + atropine; 
(e) tabun + atropine + K048. The first two groups (saline 
and K048 group) received intraperitoneally (i.p.) 2 mL kg‒1 
of saline or a 1/4 LD50 dose of K048 (LD50=238.3 mg kg
‒1 
body weight; 22), respectively. A sub-lethal dose (3/4 LD50) 
of tabun (LD50=317.5 μg kg
‒1 body weight; 22) was 
administrated subcutaneously (s.c.) to the three groups 
receiving tabun. One minute after tabun exposure, the tabun 
+ atropine group received a 10 mg kg‒1 body weight i.p. 
dose of atropine, while the tabun + atropine + K048 group 
received a combination of 1/4 LD50 K048 and atropine 
(10 mg kg‒1).
At time points 0.5 h, 1 h, and 6 h, blood samples were 
taken directly from the heart. Plasma was separated by 
centrifugation and stored at ‒20 °C until analysis. After 
isolation, the brain and diaphragm were rinsed with saline 
and stored at ‒20 °C until analysis. After thawing, 
homogenates were prepared as 100 mg mL‒1 diaphragm 
homogenate and 40 mg mL‒1 brain homogenate, diluted in 
a corresponding volume of 0.1 mol L‒1 sodium phosphate 
buffer, pH 7.4 (supplemented with 1 % Triton X-100 for 
the diaphragm sample preparation). The tissue homogenates 
were prepared using an IKA-Werke ultra turrax homogeniser 
(LABSCO, Friedberg, Germany). The homogenates were 
centrifuged at 3000 g and 4 °C for 10 min. The supernatants 
were used for the cholinesterase enzyme activity 
measurement promptly after the preparation (23).
Pharmacokinetics
The pharmacokinetics of K048 was determined in a 
group of six male Wistar rats for each time point. This group 
received the same dose as the K048 group for cholinesterase 
activity measurement (1/4 LD50; i.p.). The animals were 
narcotised with carbon dioxide, and blood taken from the 
heart through the thoracic cavity into heparin-coated tubes, 
gently mixed, and centrifuged at 3000 g and 10 °C for 
15 min (Universal 320R, Hettich, Germany) to obtain 
plasma. The animals were perfused transcardially with 
saline (0.9 % NaCl) for 8 min (50 mL min‒1). After 
perfusion, the tissues (heart, diaphragm, kidney, hind-limb 
muscle, and brain) were carefully removed. All of the 
samples were stored at ‒80 °C until HPLC analysis. The 
proteins were directly precipitated from plasma samples 
with perchloroacetic acid (300:25). The tissues were 
homogenised (using Ultra Turrax, IKA-Werke for 30 s and 
by UP50H, Hielsche Ultrasound Technology, Germany for 
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1 min) in purified water (1:4), and the proteins precipitated 
with perchloroacetic acid (300:25). The samples were 
centrifuged at 11,000 g and 10 °C for 10 min. The obtained 
supernatants were used for analyses.
HPLC separation conditions for K048 in plasma and 
tissue samples
Analytical column LiChrospher® 60 RP-select B (5 µm) 
LiChroCART® 125-4 (Merck, Damstadt, Germany) with 
guard column LiChrospher® 60 RP-select B (5 µm) was 
used for analysis. The mobile phase contained 56.2 mmol L‒1 
Na2HPO4, 47.9 mmol L
‒1 citric acid, 0.027 mmol L‒1 
Na2EDTA, 0.925 mmol L
‒1 octane sulphonic acid, and 
75:950 acetonitrile:aqueous phase. The flow rate of the 
mobile phase was 1 mL min‒1. The pH was adjusted to 3.5 
with H3PO4. Sample volume was 20 µL. All chromatograms 
were obtained at 40 °C. Samples were analysed with UV 
detection. The maximum wavelength of K048 was 275 nm.
All pharmacokinetic analyses were performed on an 
Agilent 1260 Series liquid chromatograph (Palo Alto, CA, 
USA) composed of degasser, quaternary pump, light-tight 
autosampler unit set, thermostated column compartment, 
and MS detector LCQ Fleet (Thermo Finnigan, San Jose, 
CA, USA). Agilent ChemStation software and statistical 
software Prism4 (GraphPad Software, San Diego, CA, 
USA) were used for analysis of results.
Enzyme activity assay
Plasma, diaphragm, and brain samples were analysed 
for AChE and BChE activity using the spectrophotometric 
Ellman method (24, 25). Final sample dilutions for the assay 
were: plasma - 50 times; brain - 625 times; and diaphragm 
- 66.7 times. AChE and BChE activities were distinguished 
using AChE- and BChE-selective inhibitors BW284C51 
(10 µmol L‒1) and ethopropazine (20 µmol L‒1), respectively 
(26, 27). The activity was measured in a 0.1 mol L‒1 sodium 
phosphate buffer, pH 7.4, at 25 °C using ATCh (1.0 mmol L‒1) 
and DTNB (0.3 mmol L‒1). All of the measurements were 
performed on a Cary 300 spectrophotometer (Varian Inc, 
Australia). For diaphragm samples increase in absorbance 
was monitored at 436 nm and for plasma and brain samples 
at 412 nm over 4 min. Enzyme activity was expressed as 
micromoles of ATCh hydrolysed per minute and millilitre 
of tissue homogenate (undiluted) or plasma sample from 
which ratio to control activity was calculated (% of control 
activity). For the statistical analysis we used one-way 
analysis of variance with Bonferroni correction (post hoc). 
Values p<0.05 were considered statistically significant.
RESULTS AND DISCUSSION
Figure 1 summarises K048 distribution and elimination 
across tissues. As a positively charged compound, K048 is 
quickly eliminated from the organism (28-30). In our study 
the entire dose (60 mg kg‒1 body weight) was eliminated 
within a few hours from i.p. application. This could be seen 
as an advantage of pyridinium oxime-based antidotes, but 
at the same time as a disadvantage considering effective 
therapy and dosage regimes. Moreover, earlier studies by 
Thiermann et al. (17, 31) have argued in favour of repeated 
or continuous infusion with a pyridinium oxime antidote 
to counter the persistence of OPs in the organism and ensure 
full recovery and survival.
K048’s distribution profile shows that it reaches the 
highest concentration of ≈200 μmol L‒1 in the plasma 
30 min after i.p. injection (Table 1). Considering AChE 
reactivation efficiency in vitro and the fact that pyridinium 
oximes are not metabolised in serum (32), this concentration 
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Figure 1 Rat plasma and tissue concentrations of K048 after a single i.p. dose of 238.3 mg kg‒1;(1/4 of the LD50, see ref. 20). Data are 
presented as medians with interquartile ranges. Plasma and kidney are highlighted as tissues with the highest oxime concentrations
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of K048 should suffice for AChE reactivation in vivo (10). 
The second highest concentration of K048 was observed 
in the kidneys (≈100 μmol L‒1), also half an hour after i.p. 
injection. This is not unusual, since renal clearance is the 
main elimination pathway of pyridinium oximes (28, 32). 
If we look at the other organs such as the diaphragm, skeletal 
muscle, and heart, we can see that positively charged 
pyridinium compounds have difficulty crossing biological 
barriers and not just the blood-brain barrier (maximum brain 
concentration was less than 1 μmol L‒1; 33). The problem 
of delivering oxime antidotes to the brain has been 
addressed by many approaches so far. Several groups of 
researchers have tried to synthesise uncharged oximes that 
would be able to cross the blood-brain barrier (34-38), but 
these new classes of oximes fall short of pyridinium oxime 
efficiency when it comes to tabun reactivation (37, 39). 
Much research has also been done to improve or modify 
transport of oximes across the blood-brain barrier. Some 
used membrane transporters by linking an oxime to a sugar 
moiety and some employed nanoparticles to act as carriers 
(40, 41). Resolving distribution of an antidote across the 
organism perhaps requires different approach, not 
necessarily limited to modifying oxime structure.
To get an idea of what we can expect in the sense of in 
vivo reactivation efficiency, we made calculations (Table 
1) based on reactivation constants obtained in vitro (10). 
These calculations indicate that with the obtained 
concentrations an efficient AChE reactivation of 80 % in 
the first 30 min could be expected only in the plasma/blood 
of tabun poisoned rats.
Table 2 shows cholinesterase activity in vivo in the 
control groups (animals that received saline only), which 
serve as the baseline. Tissue-specific reactivation of AChE 
and BChE activity in treated animals over time is given in 
Katalinić M, et al. Translation of in vitro to in vivo pyridinium oxime potential in tabun poisoning 
Arh Hig Rada Toksikol 2015;66:291-298
Table 1 Estimated AChE reactivation in the tissue calculated from the HPLC‒determined maximal oxime K048 concentration (Figure 
1) and based on constants obtained for K048‒assisted reactivation in vitro and the equations describing reactivation




reactivation in 30 min
Plasma 102.6 µg mL‒1 223 µmol L‒1 0.0496 78 %
Brain 0.43 µg mL‒1 0.9 µmol L‒1 0.0006 2 %
Diaphragm 2.81 µg mL‒1 6.1 µmol L‒1 0.0039 11 %
Kidney 44.6 µg mL‒1 97 µmol L‒1 0.0347 64 %
Heart 1.95 µg mL‒1 4.2 µmol L‒1 0.0027 8 %
Muscle 2.31 µg mL‒1 5.0 µmol L‒1 0.0032 9 %
*Calculations were done using kinetic constants for hAChE: k+2=0.074 min‒1, KOX=110 μmol L‒1, and equations: ln([EP]0/[EP]t)=kobs∙t 
and kobs=k+2∙[OX]/(KOX+[OX]); where [EP]0 and [EP]t are the concentrations of phosphylated enzyme at time zero and at time t, 
respectively, kobs is the observed first‒order rate constant of reactivation at any given oxime concentration [OX], KOX is the dissociation 
constant of the phosphylated enzyme‒oxime complex and k+2 is the maximum first‒order reactivation rate constant (10)
Table 2 AChE and BChE activities in control rats (n=4)
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Figures 2 and 3, respectively, and is expressed as percentage 
of the baseline. In rat plasma, AChE activity contributed to 
the total measured activity with 60 %, while the remaining 
40 % was assigned to BChE. This ratio was probably due 
to the presence of free AChE in the plasma and partial 
haemolysis of rat erythrocytes before centrifugation of the 
whole blood. In the diaphragm, AChE activity accounted 
for almost 80 % of the total measured activity, while in the 
rat brain, AChE accounted for 95 % of the total measured 
activity, which is why we omitted BChE from evaluation 
in the brain.
Therapy with K048 was effective in restoring AChE 
activity only in plasma; the highest reactivation of around 
80 % was reached within the first 30 min (Figure 2). With 
time and elimination (cf. Figure 1) this effect diminished. 
At 6 h, AChE activity dropped to the level measured in rats 
treated with tabun alone. In other words, the remaining 
tabun in plasma continued to inhibit the reactivated AChE. 
This finding confirms that it is vital to monitor AChE plasma 
activity during therapy and to adapt and repeat antidote 
dosing not only to keep AChE activity recovered but also 
to bioscavenge the remaining OP with the antidote before 
it affects the brain and other vital organs. In the diaphragm 
or the brain K048 did not significantly restore enzyme 
activity. These results confirm our extrapolation of the in 
vitro to in vivo data based on the oxime’s tissue-specific 
concentrations.
In addition, it was interesting to see the extent of AChE 
inhibition in each tissue (cf. Fig. 2). In plasma it was 
significant. In the brain, AChE inhibition was evident 
shortly after tabun injection, but it did not drop below 30 % 
of the control group. In the diaphragm, AChE inhibition 
was not as severe as would be expected and stayed within 
40-50 % of the control value at all time points. A similar 
tissue-specific distribution was reported for other nerve 
agents like sarin, cyclosarin, VR, and VX (42).
Figure 2 The effects of oxime K048 on AChE activity in the plasma, brain, and diaphragm of tabun-poisoned rats after 0.5, 1, and 6 h 
of therapy. Activity is expressed as the percentage of mean control activity (Table 2). K048 alone did not affect AChE activity and is 
not shown. Data are presented as medians with interquartile ranges. Statistical significance was determined using one-way analysis 
of variance and Bonferroni correction. Differences were considered significant when p<0.05
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According to in vitro data, K048-assisted reactivation 
of tabun-inhibited BChE should be insignificant (11). In 
other words, kinetic constants of kmax=0.0022 min‒1 and 
KOX=630 μmol L‒1 predict a reactivation maximum of only 
2 % with pharmacokinetically determined oxime plasma 
concentration (230 μmol L‒1 in 30 min, cf. Table 1). Indeed, 
according to the in vivo results (Figure 3), K048 therapy 
did not preserve BChE activity in any of the tested samples, 
which confirms that BChE in combination with K048 can 
act only as a stoichiometric scavenger of tabun and not as 
a catalytic one.
In conclusion, our results show that it is possible to 
correlate in vitro to in vivo AChE or BChE reactivation 
efficiency based only on well-determined kinetic constants. 
This approach should be applicable for future research of 
pyridinium oximes. However, this extrapolation would not 
be possible without us knowing the exact concentration of 
the oxime in a specific tissue after application. Therefore, 
pharmacokinetic studies should be planned for the early 
stages of antidote development. Pharmacokinetic profile 
can also be predicted with in silico models as a way to select 
a promising compound before performing in vivo 
experiments (43).
Other possible in vitro effects beyond cholinesterase 
reactivation are also concentration-dependant (44, 45), such 
as muscle regeneration efficiency, interaction with 
cholinergic receptors, cell viability, and oxidative stress, all 
of which can contribute to or diminish the outcome of 
therapy. Furthermore, future oxime development should 
focus on improving distribution across the organism to 
overcome maybe the main hindrance in improving therapy. 
Current antidotal research mostly revolves around passive 
diffusion linked to lipophilicity (46, 47). This perspective 
requires changing the oxime’s structure to obtain more 
desirable properties, but such changes greatly affect the 
oxime’s potency to reactivate inhibited cholinesterases. A 
step in the right direction could be to consider active 
transport or involvement of transporters as a way of 
improving therapy (48). Maybe in doing so, and based on 
wide experimental background obtained so far, we can reach 
a milestone we set out to achieve decades ago.
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Translacija učinkovitosti piridinijevih oksima kod trovanja tabunom iz in vitro sustava u in vivo primjenu
Iako su organofosforni živčani bojni otrovi potpuno zabranjeni za upotrebu, njihova je prisutnost i dalje velik problem, 
posebice kao kemijsko oružje u terorističkim napadima (poput nedavnih u Siriji). Oksimi koji se danas koriste kao 
protuotrovi u tretmanu nemaju dostatno djelovanje na reaktivaciju aktivnosti kolinesteraza, glavnih meta djelovanja 
organofosfornih spojeva. Valja napomenuti kako se klinička testiranja ovih protuotrova rijetko provode zbog svoje iznimne 
specifičnosti. Tijekom zadnjih desetljeća učinjen je napredak u istraživanju novih učinkovitijih protuotrova, međutim još 
je uvijek veliki nedostatak u poboljšavanju terapije translacija in vitro dobivenih rezultata u in vivo primjenu. Ovom 
studijom ispitali smo mogućnosti ekstrapolacije reaktivacijske učinkovitosti određene za oksimske protuotrove iz in vitro 
u in vivo sustav. Naši rezultati pokazuju kako je ova translacija moguća uz detaljno određene kinetičke parametre in vitro 
i uz poznavanje distribucije oksima i vremena cirkulacije u organizmu. Takav rezultat ističe važnost planiranja i 
farmakokinetičkih istraživanja već u samom početku razvoja protuotrova. Također, poseban naglasak u istraživanju trebalo 
bi staviti i na poboljšanje tkivo-specifične distribucije oksima u organizmu čime bi se poboljšala cjelokupna terapijska 
učinkovitost.
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